Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
Part of paid clinical trials in Indianapolis, Indiana.
- Sponsor
- Indiana University
- Study ID
- NCT05346796
- Status
- Recruiting
Conditions
- Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 99 Years
- Healthy Volunteers
- Accepted
Interventions
- Survivorship Care Plan-Personal Health Record (SCP-PHR) — BEHAVIORALThe SCP-PHR tool is an online portal that is intended to help cancer survivors manage their survivorship care.
Study Details
To understand the effectiveness and implementation of the SCP-PHR, we will conduct a hybrid type 1 effectiveness-implementation trial consisting of the following components: (A) a randomized clinical effectiveness trial, and (B) a mixed methods implementation study.
Key Dates
- Start date
- Sep 9, 2022
- Status verified
- Apr 2025
- Primary completion
- May 31, 2027
- Completion
- May 31, 2027
Study Design
- Enrollment
- 250 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- SUPPORTIVE_CARE
Arms
- No Intervention: ControlGroup that will receive written survivorship care information.
- Experimental: InterventionGroup that will be provided access to the survivorship care plan-personal health record tool.
Primary Outcome Measure
Colorectal Cancer Surveillance Outcomes [ Time Frame: 12 months ]
Central Contacts
- David A Haggstrom, MD(317) 274-9000
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Indiana University School of Medicine | Indianapolis | Indiana | 46202 | David A Haggstrom, MD, MAS (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Indianapolis, IN
By research site
Related Studies
- Childhood Cancer Survivor StudyRecruiting · St. Jude Children's Research Hospital · Birmingham, Alabama
- Daily Hand-Held Vibration TherapyRecruiting · Indiana University · Avon, Indiana
- An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid TumorsPHASE1 · Recruiting · Shenzhen Ionova Life Sciences Co., Ltd. · Lafayette, Indiana
- TTX-080 HLA-G Antagonist in Subjects With Advanced CancersPHASE1 · Recruiting · Tizona Therapeutics, Inc · Tucson, Arizona